

证券代码:688192 证券简称:迪哲医药 迪哲(江苏)医药股份有限公司 2022年第一季度报告

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Revenue, Profit, Cash Flow, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Non-recurring gains/losses, R&D expenses, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

三、其他提醒事项 需特别关注的事项:关于本报告期经营情况的其他重要信息

证券代码:0214205 证券简称:联华生物 江苏硕世生物科技股份有限公司 2022年第一季度报告

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Revenue, Profit, Cash Flow, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Non-recurring gains/losses, R&D expenses, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

三、其他提醒事项 需特别关注的事项:关于本报告期经营情况的其他重要信息

证券代码:688399 证券简称:联华生物 江苏硕世生物科技股份有限公司 2022年第一季度报告

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Revenue, Profit, Cash Flow, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Non-recurring gains/losses, R&D expenses, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

三、其他提醒事项 需特别关注的事项:关于本报告期经营情况的其他重要信息

证券代码:688399 证券简称:联华生物 江苏硕世生物科技股份有限公司 2022年第一季度报告

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Revenue, Profit, Cash Flow, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Non-recurring gains/losses, R&D expenses, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

Table with 3 columns: Item, Current Period, Comparison with Last Period. Rows include Shareholder Information, Shareholding Structure, etc.

三、其他提醒事项 需特别关注的事项:关于本报告期经营情况的其他重要信息

北京神州细胞生物技术集团股份公司 自愿披露关于控股子公司产品 SCTV01C 和 SCTV01E 获得阿联酋 III 期临床试验 批件的公告

WHO 认定的主要变异株(Delta+Omicron)的重组 S 三聚体蛋白抗原,均采用传统佐剂佐剂更显著增 强 T1 细胞的水包型佐剂,临床前毒性和非临床毒理学研究,该重组蛋白抗原模拟了 S 蛋白的 天然三聚体结构,具有更高、更稳定和稳定性好等特点,可诱导针对 WHO 认定的主要变异株的高 滴度中和抗体和 T1 细胞毒性 T 细胞免疫反应,且与单价亚单位疫苗相比,可开发更优、更广谱的 变异株中和抗体滴度,可更有效阻断变异株特别是近期全球流行毒株 Omicron 的感染风险。

北京神州细胞生物技术集团股份公司 自愿披露关于控股子公司产品 SCTV01C 和 SCTV01E 获得阿联酋 III 期临床试验 批件的公告